Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma.

A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma. Chemotherapy. 2009; 55(5):321-6.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.